153 related articles for article (PubMed ID: 12715755)
1. Recombinant DNA product for rheumatoid arthritis.
FDA Consum; 2003; 37(2):5. PubMed ID: 12715755
[No Abstract] [Full Text] [Related]
2. Adalimumab for rheumatoid arthritis?
Ebell M; Kripke C
Am Fam Physician; 2006 Feb; 73(3):435-6. PubMed ID: 16479667
[No Abstract] [Full Text] [Related]
3. Tumor necrosis factor inhibitors for rheumatoid arthritis.
Scott DL; Kingsley GH
N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
[No Abstract] [Full Text] [Related]
4. Rheumatoid arthritis.
Burchini G; Orsi C
N Engl J Med; 2004 Sep; 351(13):1360-1; author reply 1360-1. PubMed ID: 15385669
[No Abstract] [Full Text] [Related]
5. Graves' disease in a patient with rheumatoid arthritis during treatment with anti-tumor necrosis factor-alpha.
van Lieshout AW; Creemers MC; Radstake TR; Elving LD; van Riel PL
J Rheumatol; 2008 May; 35(5):938-9. PubMed ID: 18464319
[No Abstract] [Full Text] [Related]
6. New drugs for rheumatoid arthritis.
Messori A; Santarlasci B; Vaiani M
N Engl J Med; 2004 Aug; 351(9):937-8. PubMed ID: 15329436
[No Abstract] [Full Text] [Related]
7. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
Nagashima T; Minota S
J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
[No Abstract] [Full Text] [Related]
8. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
Hyrich KL; Silman AJ
J Rheumatol; 2006 May; 33(5):831-3. PubMed ID: 16652412
[No Abstract] [Full Text] [Related]
9. [Pharmacotherapy of rheumatoid arthritis in the era of genetically engineered biological preparations].
Nasonov EL
Ter Arkh; 2007; 79(5):5-8. PubMed ID: 17672066
[No Abstract] [Full Text] [Related]
10. FDA OKs two new uses for biologic arthritis drug adalimumab.
Health News; 2006 Jan; 12(1):2. PubMed ID: 16447312
[No Abstract] [Full Text] [Related]
11. [Biological agents for therapy of rheumatoid arthritis--overview].
Takeuchi T
Nihon Rinsho; 2005 Jan; 63 Suppl 1():513-6. PubMed ID: 15799409
[No Abstract] [Full Text] [Related]
12. Adalimumab therapy in rheumatoid arthritis.
Keystone E; Haraoui B
Rheum Dis Clin North Am; 2004 May; 30(2):349-64, vii. PubMed ID: 15172045
[TBL] [Abstract][Full Text] [Related]
13. New drugs for rheumatoid arthritis.
Olsen NJ; Stein CM
N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
[No Abstract] [Full Text] [Related]
14. Anti-TNF-alpha therapies: they are all the same (aren't they?).
Mpofu S; Fatima F; Moots RJ
Rheumatology (Oxford); 2005 Mar; 44(3):271-3. PubMed ID: 15561736
[No Abstract] [Full Text] [Related]
15. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001).
Ledingham J; Deighton C;
Rheumatology (Oxford); 2005 Feb; 44(2):157-63. PubMed ID: 15637039
[No Abstract] [Full Text] [Related]
16. Tumor necrosis factor inhibition: a part of the solution or a part of the problem of heart failure in rheumatoid arthritis?
Gabriel SE
Arthritis Rheum; 2008 Mar; 58(3):637-40. PubMed ID: 18311805
[No Abstract] [Full Text] [Related]
17. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
18. Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study.
Cavanagh J; Paterson C; McLean J; Pimlott S; McDonald M; Patterson J; Wyper D; McInnes I
Ann Rheum Dis; 2010 Jun; 69(6):1251-2. PubMed ID: 20371552
[No Abstract] [Full Text] [Related]
19. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
[No Abstract] [Full Text] [Related]
20. [Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].
Tomono K; Hashimoto S
Nihon Rinsho; 2005 Jan; 63 Suppl 1():573-8. PubMed ID: 15799420
[No Abstract] [Full Text] [Related]
[Next] [New Search]
